Tag: HFpEF
Medtronic initiates global study examining cardiac pacing in HFpEF patients
Medtronic has announced the initiation of a pivotal study evaluating the use of elevated and personalised cardiac pacing rates for the treatment of patients...
BioCardia announces FDA review completion of ongoing cell therapy for heart...
BioCardia, a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, has announced that the US Food and Drug...
Systemic delivery of extracellular vesicles reduces AF in heart failure with...
A recent study has provided new mechanistic insights identifying distinct atrial electrophysiological remodelling and fibrosis-associated conduction abnormalities favouring atrial fibrillation (AF) susceptibility in heart...
UK regulator approves dapagliflozin for use in heart failure across the...
AstraZeneca has today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin (Forxiga) in Great Britain...